

Thomas Muster

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11902169/thomas-muster-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

3,104
citations

20
h-index

34
g-index

34
ext. papers

3,317
ext. citations

5.1
avg, IF

3.97
L-index

#	Paper	IF	Citations
31	Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. <i>Virology</i> , 1998 , 252, 324-30	3.6	812
30	Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. <i>Journal of Virology</i> , 2000 , 74, 7989-96	6.6	482
29	Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. <i>Journal of Virology</i> , 2000 , 74, 11566-73	6.6	459
28	Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. <i>Journal of Virology</i> , 2000 , 74, 6203-6	6.6	301
27	Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. <i>Journal of Virology</i> , 1998 , 72, 6437-41	6.6	164
26	An endogenous retrovirus derived from human melanoma cells. <i>Cancer Research</i> , 2003 , 63, 8735-41	10.1	123
25	A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. <i>Journal of Infectious Diseases</i> , 2010 , 201, 354-62	7.62	104
24	Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. <i>Journal of Virology</i> , 2002 , 76, 1206-12	6.6	95
23	Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. <i>PLoS ONE</i> , 2011 , 6, e18577	3.7	59
22	Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. <i>PLoS ONE</i> , 2009 , 4, e5984	3.7	55
21	Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. <i>International Journal of Cancer</i> , 2004 , 110, 15-21	7.5	47
20	Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. <i>Journal of Infectious Diseases</i> , 1998 , 178, 1359-68	7	44
19	Development of novel influenza virus vaccines and vectors. <i>Journal of Infectious Diseases</i> , 1997 , 176 Suppl 1, S45-9	7	35
18	Expression of human endogenous retrovirus K is stimulated by ultraviolet radiation in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 656-65	4.5	32
17	Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. <i>Vaccine</i> , 2013 , 31, 6194-200	4.1	31
16	Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. <i>PLoS ONE</i> , 2012 , 7, e36506	3.7	31
15	Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. <i>PLoS ONE</i> , 2012 , 7, e39921	3.7	30

14	Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. <i>Vaccine</i> , 2011 , 29, 3517-24	4.1	28
13	Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography. <i>Vaccine</i> , 2014 , 32, 2487-92	4.1	27
12	Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. <i>Vaccine</i> , 2009 , 27, 2851-7	4.1	27
11	Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. <i>Journal of Virology</i> , 2011 , 85, 2469-73	6.6	19
10	Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. <i>Medical Microbiology and Immunology</i> , 2010 , 199, 93-101	4	19
9	Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice. <i>Journal of General Virology</i> , 2009 , 90, 366-374	4.9	19
8	Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines. <i>Biotechnology Journal</i> , 2014 , 9, 405-14	5.6	15
7	Sequence variability of retroviral particles derived from human melanoma cells melanoma-associated retrovirus. <i>Virus Research</i> , 2007 , 123, 211-5	6.4	12
6	Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. <i>Journal of Virology</i> , 2011 , 85, 11139-45	6.6	11
5	Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. <i>Vaccine</i> , 2019 , 37, 3722-3729	4.1	7
4	Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. <i>PLoS ONE</i> , 2015 , 10, e0138722	3.7	7
3	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. <i>Scientific Reports</i> , 2021 , 11, 22164	4.9	3
2	A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice. <i>Archives of Virology</i> , 2015 , 160, 2525-34	2.6	2
1	Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients. <i>PLoS ONE</i> , 2021 , 16, e0260155	3.7	2